Cell line · CVCL_1625
OPM-2
Cancer cell line, Homo sapiens. Plasma cell myeloma. 60 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. OPM-2. Cell lines, record CVCL_1625. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1625
On this page
Cell line
As Cellosaurus gives it.
- Name
- OPM-2
- Accession
- CVCL_1625
- RRID
- RRID:CVCL_1625
- Synonyms
- OPM2
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 56Y
- Category
- Cancer cell line
- Diseases
- Plasma cell myeloma (NCIt C3242); Multiple myeloma (ORDO Orphanet_29073)
- Derived from
- Peripheral blood (in situ)
- Cell type
- Plasma cell
- Entry created
- 2012-04-04
- Entry updated
- 2025-08-14
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers60
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma. | Clin Pharmacol Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An enhancement of extrachromosomal circular DNA enrichment and amplification to address the extremely low overlap between replicates. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Anti-myeloma activity of the CXCR4 antagonist WZ811. | J Mol Med (Berl) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 60
See all 60 papersRelatives3
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | OPM-2/BR | CVCL_VJ35 | Cell lines | |
| Derived from it | OPM-2/BTZ | CVCL_4V72 | Cell lines | |
| From the same person | OPM-1 | CVCL_5210 | Cell lines |
Cell banks1
| Cell bank | Catalog number | Status |
|---|---|---|
| DSMZ | ACC-50 |
Source DSMZ
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1625
GET https://conductscience.org/api/cell-lines/v1/CVCL_1625/papers?page=2